Author name: Emily Crane

Emily Crane is a writer, producer, and editor who has covered politics, health, business, and finance for publications like The Atlantic. She's also the host of the All Work All Play Podcast. She graduated from Northwestern University's Medill School of Journalism with a focus on investigative reporting and data visualization.

Avatar of Emily Crane
KNRXVALAWJHOTLRUUXT6K5RCBY

Passive beauty: The rise of simplified, long-term skin care

Fashion & Beauty / By

Consumer demand for preventative beauty routines and holistic wellness practices is reshaping the beauty and personal care (BPC) industry. According to a recent report from Mintel, 80% of adults are adopting a preventative approach to their beauty routines, prioritizing consistent, long-term care over reactive solutions. This trend is prompting manufacturers to innovate and communicate clear […]

Passive beauty: The rise of simplified, long-term skin care Read More »

X2LSAZ6VSVAOXITJ6CF4KFBZ5E

How US cosmetics companies can turn regulatory compliance into a competitive edge

Fashion & Beauty / By

As regulatory pressures mount across the US cosmetics and personal care industry, non-compliance costs are rising. According to the “2025 State of Regulatory Affairs and Compliance Survey Report” from RegAsk, a software company, 42% of regulatory professionals say their organizations have missed at least one regulatory requirement, leading to delayed product launches, revenue loss, and

How US cosmetics companies can turn regulatory compliance into a competitive edge Read More »

Data center boom powers rebound in construction planning

Building & Construction / By

Nonresidential construction planning rebounded in December, driven by a sharp uptick in data center and warehouse projects, according to Dodge Construction Network. The Dodge Momentum Index, a benchmark that measures nonresidential construction planning, climbed 10.2% to close 2024. Commercial planning led the charge with a 14.2% increase, while institutional planning posted a more modest 2.5%

Data center boom powers rebound in construction planning Read More »

Resolve to win more jobs in the new year

Building & Construction / By

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Matt Verderamo is a consultant at Well Built Construction Consulting, a Baltimore-based firm that delivers strategic consulting, facilitation services and peer roundtables for construction executives. Opinions are the author’s own. I often work with construction companies that

Resolve to win more jobs in the new year Read More »

lucidair3web 1200x630 s

Used Vehicle Values Stabilize for 2024 as Inventory Tightens

Automotive / By

Electric vehicle values were higher in December versus November and stronger than the industry average overall, increasing by 3.4%, while non-EVs fell 0.5% over the same time.  Photo: Martin Romjue / Bobit After seeing used-vehicle values depreciate more than normal in the first half of the year, the Manheim Used Vehicle Value Index

Used Vehicle Values Stabilize for 2024 as Inventory Tightens Read More »

All Work All Play Podcast

Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says

Health & Fitness / By

Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday.  That opens the door for broader access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss. Demand for the injection has soared over the last year despite

Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says Read More »

108018062 1723129535438 gettyimages 2126120280 ZEPBOUND PATIENT SHORTAGES

Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise

Health & Fitness / By

Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to

Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise Read More »

Start typing and press enter to search

Scroll to Top